Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration

Immunology and Cell Biology

Volumn 91, Issue 9, 2013, Pages 583-592

  O'Sullivan, David ^a   Miller, John H ^a   Northcote, Peter T ^a   La Flamme, Anne Camille ^a,b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

Author keywords

drug synergy; EAE MS; inflammation; microtubule stabilizing agents; migration; proliferation

Indexed keywords

ANTIMITOTIC AGENT; DOCETAXEL; IXABEPILONE; PACLITAXEL; PELORUSIDE A; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOANTIGENS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SYNERGISM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPOTHILONES; GROWTH INHIBITORS; HUMANS; LACTONES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULES; MULTIPLE SCLEROSIS; PACLITAXEL; TAXOIDS;

EID: 84885474186     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.47     Document Type: Article

References (45)

1. Lutton JD, Winston R, Rodman TC. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med 2004; 229: 12-20. (Pubitemid 38101674)
2. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025. (Pubitemid 36026580)
3. Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol Ther 2006; 109: 198-209. (Pubitemid 41740821)
4. Altmann KH. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 2001; 5: 424-431.
5. Brahn E, Tang C, Banquerigo ML. Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum 1994; 37: 839-845. (Pubitemid 24184535)
6. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994; 157: 291-299. (Pubitemid 24259471)
7. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004; 50: 533-540. (Pubitemid 38393162)
8. Cao L, Sun D, Cruz T, Moscarello MA, Ludwin SK, Whitaker JN. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J. Neuroimmunol 2000; 108: 103-111. (Pubitemid 30438757)
9. Crume KP, O'Sullivan D, Miller JH, Northcote PT, La Flamme AC. Delaying the onset of experimental autoimmune encephalomyelitis with the microtubule-stabilizing compounds, paclitaxel and Peloruside A. J Leukoc Biol 2009; 86: 949-958.
10. Song YW, Kim HA, Baek HJ, Lee EB, Chung ES, Hong KM. Paclitaxel reduces antidsDNA antibody titer and BUN, prolonging survival in murine lupus. Int J Immunopharmacol 1998; 20: 669-677. (Pubitemid 28535149)
11. Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 2003; 3: 1699-1714. (Pubitemid 37421260)
12. Cobham MV, Donovan D. Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. Cancer Manag Res 2009; 1: 69-77.
13. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-1437. (Pubitemid 32708699)
14. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161: 4437-4446. (Pubitemid 28469031)
15. Hofstetter HH, Forsthuber TG. Kinetics of IL-17- and interferon-gamma- producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice. Neurosci Lett 2010; 476: 150-155.
16. Targoni OS, Baus J, Hofstetter HH, Hesse MD, Karulin AY, Boehm BO et al. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis. J Immunol 2001; 166: 4757-4764. (Pubitemid 32233765)
17. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003; 197: 1073-1081. (Pubitemid 36570063)
18. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 2004; 75: 388-397. (Pubitemid 38316367)
19. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671. (Pubitemid 20356243)
20. Wilmes A, O'Sullivan D, Chan A, Chandrahasen C, Paterson I, Northcote PT et al. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol 2011; 68: 117-126.
21. Murphy AC, Lalor SJ, Lynch MA, Mills KH. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010; 24: 641-651.
22. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010; 9: 883-897.
23. Owens T, Tran E, Hassan-Zahraee M, Krakowski M. Immune cell entry to the CNS-a focus for immunoregulation of EAE. Res Immunol 1998; 149: 781-789.
24. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14: 1142-1149.
25. Carlson T, Kroenke M, Rao P, Lane TE, Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008; 205: 811-823. (Pubitemid 351549880)
26. Friedl P, Weigelin B. Interstitial leukocyte migration and immune function. Nat Immunol 2008; 9: 960-969.
27. Sanchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. EMBO J 1999; 18: 501-511. (Pubitemid 29057235)
28. Watanabe T, Noritake J, Kaibuchi K. Regulation of microtubules in cell migration. Trends Cell Biol 2005; 15: 76-83. (Pubitemid 40188217)
29. Mamdouh Z, Kreitzer GE, Muller WA. Leukocyte transmigration requires kinesinmediated microtubule-dependent membrane trafficking from the lateral border recycling compartment. J Exp Med 2008; 205: 951-966. (Pubitemid 351549890)
30. Loubani O, Hoskin DW. Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression. Anticancer Res 2005; 25: 735-741. (Pubitemid 40546839)
31. Roberts RL, Nath J, Friedman MM, Gallin JI. Effects of taxol on human neutrophils. J Immunol 1982; 129: 2134-2141. (Pubitemid 12004383)
32. Lautenschlager F, Paschke S, Schinkinger S, Bruel A, Beil M, Guck J. The regulatory role of cell mechanics for migration of differentiating myeloid cells. Proc Natl Acad Sci USA 2009; 106: 15696-15701.
33. Mamdouh Z, Mikhailov A, Muller WA. Transcellular migration of leukocytes is mediated by the endothelial lateral border recycling compartment. J ExpMed 2009; 206: 2795-2808.
34. Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M et al. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 2004; 64: 8924-8931. (Pubitemid 39665499)
35. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res 2007; 24: 1691-1701. (Pubitemid 47206619)
36. Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res 2009; 155: 142-146.
37. Elhofy A, Kennedy KJ, Fife BT, Karpus WJ. Regulation of experimental autoimmune encephalomyelitis by chemokines and chemokine receptors. Immunol Res 2002; 25: 167-175. (Pubitemid 34264102)
38. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK et al. Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006; 70: 1555-1564.
39. Gapud EJ, Bai R, Ghosh AK, Hamel E. Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously. Mol Pharmacol 2004; 66: 113-121. (Pubitemid 38822093)
40. Huang GS, Lopez-Barcons L, Freeze BS, Smith AB, Goldberg GL, Horwitz SB et al. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograftbearing mice. Clin Cancer Res 2006; 12: 298-304. (Pubitemid 43166207)
41. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6: 1978-1987. (Pubitemid 30305097)
42. Lu H, Murtagh J, Schwartz EL. The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel (taxotere). Mol Pharmacol 2006; 69: 1207-1215.
43. West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000; 65: 445-449. (Pubitemid 30061125)
44. Weir C, McNeill A, Hook S, Harvie M, La Flamme AC, Le Gros G et al. Critical role of preproenkephalin in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 179: 18-25. (Pubitemid 44441596)
45. Keating P, O'Sullivan D, Tierney JB, Kenwright D, Mirmoeini S, Mawasse L et al. Protection from EAE by IL-4Ralpha(-/-) macrophages depends upon T regulatory cell involvement. Immunol Cell Biol 2009; 87: 534-545.